Abstract:
The invention consists of: (1) cloned Sorangium cellulosum polyketide synthase (PKS) biosynthetic cluster DNA; and (2) the nucleotide sequence and predicted protein coding sequences of the cloned DNA. The invention can be used for, but not limited to: (a) increasing yields of PKS product in Sorangium cellulosum (e.g., by amplification or genetic modification of the epothilone gene cluster or its component parts); (b) increasing yields of polyketide product in a heterologous system by transfer of the epothilone gene cluster or its component parts, which may be followed by amplification or genetic modification of the PKS gene cluster or its component parts; (c) modification of the polyketide product chemical structure in either Sorangium cellulosum or a heterologous host (e.g., by genetic modification of the epothilone gene cluster or its component parts; and (d) for the detection of genes and gene products involved in making polyketides or related molecules in other organisms (e.g., by hybridization or complementation assays). DNA sequence and analysis is presented for the following cosmids and plasmids: A2 cosmid; the pEPOcos6 region (overlapping of pEPOcos6 and pEPOcos7); pEPOcos8 cosmid; A5 cosmid; Sau4 (10 kb plasmid).
Abstract:
The invention consists of: (1) cloned Sorangium cellulosum polyketide synthase (PKS) biosynthetic cluster DNA; and (2) the nucleotide sequence and predicted protein coding sequences of the cloned DNA. The invention can be used for, but not limited to: (a) increasing yields of PKS product in Sorangium cellulosum (e.g., by amplification or genetic modification of the epothilone gene cluster or its component parts); (b) increasing yields of polyketide product in a heterologous system by transfer of the epothilone gene cluster or its component parts, which may be followed by amplification or genetic modification of the PKS gene cluster or its component parts; (c) modification of the polyketide product chemical structure in either Sorangium cellulosum or a heterologous host (e.g., by genetic modification of the epothilone gene cluster or its component parts; and (d) for the detection of genes and gene products involved in making polyketides or related molecules in other organisms (e.g., by hybridization or complementation assays). DNA sequence and analysis is presented for the following cosmids and plasmids: A2 cosmid; the pEPOcos6 region (overlapping of pEPOcos6 and pEPOcos7); pEPOcos8 cosmid; A5 cosmid; Sau4 (10 kb plasmid).
Abstract:
This invention relates to a recombinant Pichia pastoris formate dehydrogenase (FDH) enzyme that catalyzes the oxidation of formate to carbon dioxide and the simultaneous reduction of nicotinamide adenine dinucleotide (NAD+) to its reduced form (NADH). Also related are isolated nucleic acids encoding P. pastoris FDH polypeptides, and fragments and variants thereof, as well as vectors and host cells comprising these nucleic acids. Further related are isolated, recombinant P. pastoris FDH polypeptides, and fragments and variants thereof, and antibodies that specifically bind to P. pastoris FDH polypeptides, fragments, or variants. The invention also relates to methods of obtaining isolated P. pastoris FDH nucleic acids, polypeptides, and antibodies, and methods of using P. pastoris FDH in various reactions for industrial or pharmaceutical applications.
Abstract:
This invention relates to a recombinant Pichia pastoris formate dehydrogenase (FDH) enzyme that catalyzes the oxidation of formate to carbon dioxide and the simultaneous reduction of nicotinamide adenine dinucleotide (NAD+) to its reduced form (NADH). Also related are isolated nucleic acids encoding P. pastoris FDH polypeptides, and fragments and variants thereof, as well as vectors and host cells comprising these nucleic acids. Further related are isolated, recombinant P. pastoris FDH polypeptides, and fragments and variants thereof, and antibodies that specifically bind to P. pastoris FDH polypeptides, fragments, or variants. The invention also relates to methods of obtaining isolated P. pastoris FDH nucleic acids, polypeptides, and antibodies, and methods of using P. pastoris FDH in various reactions for industrial or pharmaceutical applications.
Abstract:
An enzymatic hydroxylation process for the preparation of compounds useful as HMG-CoA reductase inhibitors and/or as intermediates in the preparation of HMG-CoA reductase inhibitors uses a microorganism or an enzyme derived from, or having the structure of an enzyme derived from, said microorganism, which is capable of catalyzing the hydroxylation process.
Abstract:
An enzymatic hydroxylation process for the preparation of compounds useful as HMG-CoA reductase inhibitors and/or as intermediates in the preparation of HMG-CoA reductase inhibitors uses a microorganism or an enzyme derived from, or having the structure of an enzyme derived from, said microorganism, which is capable of catalyzing the hydroxylation process.
Abstract:
An enzymatic hydroxylation process for the preparation of compounds useful as HMG-CoA reductase inhibitors and/or as intermediates in the preparation of HMG-CoA reductase inhibitors uses a microorganism or an enzyme derived from, or having the structure of an enzyme derived from, said microorganism, which is capable of catalyzing the hydroxylation process.
Abstract:
This invention relates to a recombinant Pichia pastoris formate dehydrogenase (FDH) enzyme that catalyzes the oxidation of formate to carbon dioxide and the simultaneous reduction of nicotinamide adenine dinucleotide (NAD+) to its reduced form (NADH). Also related are isolated nucleic acids encoding P. pastoris FDH polypeptides, and fragments and variants thereof, as well as vectors and host cells comprising these nucleic acids. Further related are isolated, recombinant P. pastoris FDH polypeptides, and fragments and variants thereof, and antibodies that specifically bind to P. pastoris FDH polypeptides, fragments, or variants. The invention also relates to methods of obtaining isolated P. pastoris FDH nucleic acids, polypeptides, and antibodies, and methods of using P. pastoris FDH in various reactions for industrial or pharmaceutical applications.
Abstract:
An enzymatic hydroxylation process for the preparation of compounds useful as HMG-CoA reductase inhibitors and/or as intermediates in the preparation of HMG-CoA reductase inhibitors uses a microorganism or an enzyme derived from, or having the structure of an enzyme derived from, said microorganism, which is capable of catalyzing the hydroxylation process.
Abstract:
An enzymatic hydroxylation process for the preparation of compounds useful as HMG-CoA reductase inhibitors and/or as intermediates in the preparation of HMG-CoA reductase inhibitors uses a microorganism or an enzyme derived from, or having the structure of an enzyme derived from, said microorganism, which is capable of catalyzing the hydroxylation process.